Want to see ARCT full AI Analyst Report?

Arcturus Therapeutics (ARCT) Price & Analysis

2,161 Followers

ARCT Stock Chart & Stats

$8.85

-$1.70(-8.19%)

At close: Jan 08 4:00 PM EST

$8.85

-$1.70(-8.19%)

Day’s Range― - ―

52-Week Range$5.77 - $24.17

Previous CloseN/A

Volume109.32K

Average Volume (3M)829.62K

Market Cap

$171.96M

Enterprise Value$32.02

Total Cash (Recent Filing)$211.38M

Total Debt (Recent Filing)$23.99M

Price to Earnings (P/E)―

Beta2.46

Next Earnings

Aug 10, 2026

EPS Estimate

-1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.83

Shares Outstanding28,423,069

10 Day Avg. Volume934,920

30 Day Avg. Volume829,622

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)0.78

Price to Sales (P/S)2.50

P/FCF Ratio-2.26

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$20.00

Price Target Upside125.99% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

EPS Forecast (FY)-4.03

Revenue Forecast (FY)$15.29M

Bulls Say, Bears Say

Bulls Say

Cash RunwayA multi-year cash runway (~$213M to beyond Q2 2028) materially reduces near-term financing pressure, allowing Arcturus to fund planned Phase II activities, Type C/end‑of‑Phase‑II interactions and manufacturing scale-up. This liquidity supports execution of clinical/regulatory milestones without immediate dilution.

Thermo Fisher CollaborationA strategic Thermo Fisher deal for clinical manufacturing and research de‑risks scale‑up for ARCT‑032, provides end‑to‑end late‑stage support and could secure commercial supply rights. This structural outsourcing strengthens operational capacity and shortens the path to Phase 3 and potential commercialization.

Repeat‑dosing TolerabilityDemonstrated tolerability for sustained inhaled mRNA dosing is a substantive platform advance: it validates LUNAR delivery and purification approaches, differentiates Arcturus in inhaled RNA, and materially improves the technical probability of clinical success and regulatory acceptance for respiratory programs.

Bears Say

Revenue Decline & Large LossesSharp revenue contraction and deeply negative margins indicate the current cost base is not supported by sales, increasing reliance on financing or milestones. Persistent operating losses erode balance‑sheet capacity over time and raise execution risk if clinical or partner revenues disappoint.

Small, Open‑label CF StudyA small, non‑randomized Phase II limits statistical power and the strength of efficacy signals, complicating regulatory interpretation and increasing the likelihood of needing larger confirmatory trials. This design raises the chance of ambiguous results, longer development timelines and higher cumulative costs.

Revenue Concentration On PartnersHeavy dependence on collaboration, milestone and licensing income makes revenue lumpy and tied to partner decisions and timelines. Until proprietary products reach broad commercialization, cash flows remain volatile and sensitive to partner execution, regulatory outcomes, and milestone timing.

Arcturus Therapeutics News

Arcturus, Thermo Fisher deal adds support to ARCT-032 exposure, says Roth

Roth Capital analyst Adam Walsh keeps a Buy rating and $20 price target on shares of Arcturus Therapeutics...

19d ago

TMO

ARCT

Arcturus announces collaboration with Thermo Fisher to advance ARCT-032

Arcturus Therapeutics (ARCT) announced a strategic collaboration with Thermo Fisher Scientific (TMO) to help support the Phase 3...

19d ago

TMO

ARCT

Arcturus Therapeutics initiated with a Buy at Freedom Broker

Freedom Broker initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $27 price target Arcturus is...

19d ago

ARCT

Arcturus Therapeutics: Buy Rating Backed by Advancing mRNA Programs and De-Risked CF Manufacturing Partnership

Analyst Thomas Shrader of BTIG maintained a Buy rating on Arcturus Therapeutics, with a price target of $23.00....

15d ago

ARCT

Arcturus Therapeutics Announces Thermo Fisher mRNA Partnership

The latest announcement is out from Arcturus Therapeutics ( ($ARCT) ). On June 26, 2026, Arcturus Therapeutics entered...

19d ago

ARCT

Arcturus Shareholders Back Board, Pay, and Auditor

Arcturus Therapeutics ( ($ARCT) ) just unveiled an update. On June 5, 2026, Arcturus Therapeutics Holdings Inc. held...

2M ago

ARCT

Arcturus Therapeutics’ Earnings Call: mRNA Bets vs. Burn

Arcturus Therapeutics (($ARCT)) has held its Q1 earnings call. Read on for the main highlights of the call....

2M ago

ARCT

Myles Minter Reiterates Buy on Arcturus Therapeutics, Highlighting Long-Term Upside Despite More Conservative Near-Term Outlook

William Blair analyst Myles Minter has reiterated their bullish stance on ARCT stock, giving a Buy rating on...

2M ago

ARCT

ARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained

H.C. Wainwright analyst Andrew Fein has maintained their neutral stance on ARCT stock, giving a Hold rating on...

2M ago

ARCT

Arcturus Therapeutics Signals Progress Amid Revenue Slip

Arcturus Therapeutics (($ARCT)) has held its Q1 earnings call. Read on for the main highlights of the call....

2M ago

ARCT

Myles Minter Reiterates Buy on Arcturus, Citing Strengthened CF Pipeline, Reduced Competitive Pressure, and Rare-Disease Upside

William Blair analyst Myles Minter has reiterated their bullish stance on ARCT stock, giving a Buy rating today....

2M ago

ARCT

Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline

Arcturus Therapeutics ( ($ARCT) ) has provided an announcement. Arcturus Therapeutics named veteran biotech finance executive Dennis Mulroy...

2M ago

ARCT

Arcturus Therapeutics reports Q1 EPS (95c), consensus ($1.01)

Reports Q1 revenue $2.1M, consensus $6.9M. “Arcturus continues to advance its rare disease therapeutics portfolio. We have initiated...

2M ago

ARCT

ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Arcturus Therapeutics (ARCT) is scheduled to report 1st quarter earnings on 05/07/2026, after the market closes. Regarding Q1...

3M ago

ARCT

ARCT FAQ

What was Arcturus Therapeutics’s price range in the past 12 months?

Arcturus Therapeutics lowest stock price was $5.77 and its highest was $24.17 in the past 12 months.

What is Arcturus Therapeutics’s market cap?

Arcturus Therapeutics’s market cap is $171.96M.

When is Arcturus Therapeutics’s upcoming earnings report date?

Arcturus Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 20 days.

How were Arcturus Therapeutics’s earnings last quarter?

Arcturus Therapeutics released its earnings results on May 07, 2026. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.01 by $0.06.

Is Arcturus Therapeutics overvalued?

According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Arcturus Therapeutics pay dividends?

Arcturus Therapeutics pays a Notavailable dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Arcturus Therapeutics dividends here

What is Arcturus Therapeutics’s EPS estimate?

Arcturus Therapeutics’s EPS estimate is -1.

How many shares outstanding does Arcturus Therapeutics have?

Arcturus Therapeutics has 28,423,069 shares outstanding.

What happened to Arcturus Therapeutics’s price movement after its last earnings report?

Arcturus Therapeutics reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.01. Following the earnings report the stock price went up 3.596%.

Which hedge fund is a major shareholder of Arcturus Therapeutics?

Currently, no hedge funds are holding shares in ARCT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Arcturus Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-26.03%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.

Arcturus Therapeutics (ARCT) Earnings & Revenues

Historic Earnings Reports

ARCT Stock 12 Month Forecast

Average Price Target

$20.00

▲(125.99% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","28":"$28","10.75":"$10.75","16.5":"$16.5","22.25":"$22.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$27.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,10.75,16.5,22.25,28],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.89,8.436923076923076,9.983846153846153,11.53076923076923,13.077692307692306,14.624615384615385,16.17153846153846,17.718461538461536,19.265384615384615,20.81230769230769,22.35923076923077,23.906153846153845,25.45307692307692,{"y":27,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.89,7.898461538461538,8.906923076923077,9.915384615384616,10.923846153846153,11.932307692307692,12.94076923076923,13.94923076923077,14.957692307692309,15.966153846153848,16.974615384615387,17.983076923076922,18.99153846153846,{"y":20,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.89,7.052307692307692,7.214615384615384,7.3769230769230765,7.539230769230769,7.701538461538461,7.863846153846153,8.026153846153846,8.188461538461539,8.350769230769231,8.513076923076923,8.675384615384615,8.837692307692308,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.99,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.97,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.49,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.13,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.37,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.35,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.63,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.77,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.89,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >